drug
zuranolone
Marketedupdated 3mo agoby Sage Therapeutics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying zuranolone
- —A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
- —A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- phase1Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 31, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Aug 23, 2037compositionUS 11236121
- Aug 23, 2037compositionUS 11236121
- Aug 23, 2037compositionUS 11236121
- Aug 23, 2037method-of-use (U-2552)US 11884696
- Aug 23, 2037method-of-use (U-2552)US 11884696
- Aug 23, 2037method-of-use (U-2552)US 11884696
- Apr 17, 2034method-of-use (U-2552)US 10172871
- Apr 17, 2034method-of-use (U-2552)US 10172871
- Apr 17, 2034method-of-use (U-2552)US 10172871
- Apr 17, 2034method-of-use (U-2552)US 10342810
- Apr 17, 2034method-of-use (U-2552)US 10342810
- Apr 17, 2034method-of-use (U-2552)US 10342810
- Apr 17, 2034compositionUS 9512165
- Apr 17, 2034compositionUS 9512165
- Apr 17, 2034compositionUS 9512165
FDA exclusivities (3)
- Oct 31, 2028NCENew Chemical Entity (5y)2.2y
- Oct 31, 2028NCENew Chemical Entity (5y)2.2y
- Oct 31, 2028NCENew Chemical Entity (5y)2.2y
News(2)
- Supernus and Indivior merge to create CNS mega-company with 11 approved drugsSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”biospace · 11d ago
- Supernus, Indivior merge to beef up brain drug portfolioThe transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.biopharma_dive · 11d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that